StockNews.AI
REPL
StockNews.AI
12 days

Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights – REPL

1. Gross Law Firm announces class action for Replimune shareholders. 2. Allegations include false statements about the IGNYTE trial. 3. Trial inadequacies resulted in FDA classifying it as not well-controlled. 4. Shareholders can register for recovery by September 22, 2025. 5. Lawsuit aims to protect investors from misleading corporate practices.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit suggests severe operational deficiencies, negatively impacting investor sentiment and stock price. Historical instances, such as the lawsuits against Biogen, resulted in significant price drops due to similar allegations of misinformation regarding drug trials.

How important is it?

The significant allegations and class action nature indicate strong potential for price impacts. Given the history of class actions affecting share prices negatively, this case is critically relevant to REPL shareholders.

Why Long Term?

Legal proceedings often linger, potentially affecting stock price over extended periods. Similar past cases show prolonged negative impacts until resolution.

Related Companies

BIIBNVAXMDGL
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=159980&from=3 CLASS PERIOD: November 22, 2024 to July 21, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. DEADLINE: September 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=159980&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of REPL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 22, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

Related News